Press Releases NetraMark Holdings Inc. OTC Markets

Equities

AINMF

CA64119M1059

Market Closed - OTC Markets Other stock markets 02:05:14 2024-07-11 pm EDT			5-day change	1st Jan Change
0.205 ^USD	-3.21%		-6.61%	-22.17%

Jun. 10	NetraMark Holdings Inc. Announces Collaboration Agreement with National Institute of Mental Health to Analyze Clinical Trial Data on the Use of Ketamine in Mental Disorders	CI
Jun. 09	257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO ANALYZE CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC DISORDERS	Jun. 10	AQ
NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING	May. 28	AQ
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS	Apr. 10	AQ
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS	Apr. 05	AQ
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD	Apr. 04	AQ
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS	Apr. 02	AQ
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE	Mar. 12	AQ
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING	Mar. 11	AQ
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024	Feb. 29	AQ
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	Feb. 27	AQ
NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS	Feb. 26	AQ
NETRAMARK TO PRESENT NEW DATA DEMONSTRATING THE POWER OF ITS AI BASED TECHNOLOGY TO DE-RISK NEUROLOGY CLINICAL TRIALS AT ISCTM ANNUAL MEETING	Feb. 15	AQ
NETRAMARK ANNOUNCES LAUNCH OF THE NETRA AI LAB	Feb. 12	AQ
NETRAMARK SIGNS THIRD CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	Jan. 30	AQ
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates	Jan. 16	AQ
NETRAMARK SIGNS TWO CONTRACTS WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	Dec. 20	AQ
NETRAMARK SELECTS FINN PARTNERS AS ITS PUBLIC RELATIONS AGENCY OF RECORD	Nov. 20	AQ
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK AS CHIEF MEDICAL OFFICER	Nov. 06	AQ
NETRAMARK SIGNS MASTER SERVICE AGREEMENT WITH A LARGE BIOPHARMACEUTICAL COMPANY	23-10-31	AQ
NETRAMARK CLOSES PRIVATE PLACEMENT FINANCING	23-09-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NetraMark Holdings Inc. OTC Markets

Equities

AINMF

CA64119M1059

Press Releases

Filters